A Phase II Randomized, Sham-Controlled, Double-Blind, Dose-Finding Study to Assess the Efficacy and Safety of Transurethral Photodynamic Therapy With Lemuteporfin in Subjects With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.
Latest Information Update: 27 Feb 2012
Price :
$35 *
At a glance
- Drugs Lemuteporfin (Primary)
- Indications Benign prostatic hyperplasia
- Focus Therapeutic Use
- Acronyms PLUS
- Sponsors Novelion Therapeutics
- 27 Nov 2005 New trial record.